Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.

PLoS medicine - 1 Jan 2023

Fang Si, Yarmolinsky James, Gill Dipender, Bull Caroline J, Perks Claire M, Davey Smith George, Gaunt Tom R, Richardson Tom G

Abstract excerpt

BACKGROUND: Prostate cancer (PrCa) is the second most prevalent malignancy in men worldwide. Observational studies have linked the use of low-density lipoprotein cholesterol (LDL-c) lowering therapies with reduced risk of PrCa, which may potentially be attributable to confounding factors. In this study, we performed a drug target Mendelian randomisation (MR) analysis to evaluate the association of genetically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholesterol, LDL
Share to Genetic Associations and Epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genome-Wide Association Study

Share to Mendelian Randomization Analysis

Share to Polymorphism, Single Nucleotide

Share to Proprotein Convertase 9

Share to Prostatic Neoplasms

Share to Testosterone

Source

Open in PubMed Open full text

Identifiers

PMID: 36595504
DOI: 10.1371/journal.pmed.1003988
PMCID: PMC9810198

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.PMID 36595504Read ↗

Genetically proxied PCSK9 inhibition provides indication of lower prostate cancer risk: a Mendelian randomization studySemantic proximity Read ↗

Associations of blood lipids and LDL cholesterol lowering drug-targets with colorectal cancer risk: a Mendelian randomisation study.Semantic proximity Read ↗

Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.Semantic proximity Read ↗

Lipids, lipid-modifying drug Target genes and Bladder cancer: a Mendelian randomization studySemantic proximity Read ↗

Associations of Lipid-Lowering Drugs With Blood Pressure and Fasting Glucose: A Mendelian Randomization Study.Semantic proximity Read ↗

Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis.Semantic proximity Read ↗

Association between genetically proxied HMGCR inhibition and male reproductive health: A Mendelian randomization study.Semantic proximity Read ↗

Drug-target Mendelian randomization revealed a significant association of genetically proxied metformin effects with increased prostate cancer risk.Semantic proximity Read ↗

Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.Semantic proximity Read ↗

Genetically-proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancersSemantic proximity Read ↗

Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.Semantic proximity Read ↗

Effects of genetically proxied statins on diabetic nephropathy and retinopathy: a Mendelian randomization study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.